Kornimate/medical-research-clean huggingface dataset:
idropper usability in glaucoma

Conditions: Glaucoma, Open-Angle [C11.525.381.407]

Summary: the purpose of this study is to evaluate the usability of a medication management support system for glaucoma patients self-administering eye drops named idropper. the idropper system is a home-based ocular medication management system that reminds, instructs, dispenses, and records eye drop medication usage. the idropper system will be evaluated among a cohort of glaucoma subjects self-administering eye drops for 4-weeks.

glaucoma is a leading cause of vision loss in the united states, impacting the lives of \~4 million people. left untreated or inadequately managed, it causes blindness -- the second ranking cause of blindness in the world as well as the leader among african americans. estimates project 79.6 million glaucoma diagnoses worldwide by 2020; of these, 74% will have open-angle glaucoma (oag), which occurs virtually without symptoms. the explanation for such strikingly high disease prevalence and blindness rates is partially due to the asymptomatic nature of glaucoma. however, deficient adherence to glaucoma ocular hypotensive drops is a significant and escalating health care problem. glaucoma eye drops are often the first therapeutic choice and very effective at controlling intraocular pressure (iop) to prevent eye damage. however, glaucoma is a chronic condition and daily dosing regimens for medications can be complex and difficult to manage with impaired vision. consequently, adherence and persistence to glaucoma eye drop regimens over time becomes quite poor. overwhelming research brings the unwelcome conclusion that long term persistence with glaucoma medication is 33-39% at one year and positively contributes to blindness. currently, no mechanism exists for supporting and monitoring glaucoma eye drop compliance. the purpose of this study is to evaluate the usability of a medication management support system for glaucoma patients self-administering eye drops named idropper. the idropper system is a home-based ocular medication management system that reminds, instructs, dispenses, and records eye drop medication usage. the idropper system will be evaluated among a cohort of glaucoma subjects self-administering eye drops for 4-weeks. at study conclusion usability and satisfaction assessments will be performed to evaluate idropper system performance.

Eligibility criteria:
inclusion criteria: * at least 21 years of age; * physician diagnosis of: open angle glaucoma, angle-closure glaucoma, glaucoma suspect, or ocular hypertension * responsible for self-administration of eye drops. * no surgery within the prior 3 months; * able to speak and read english; exclusion criteria: * having any concurrent medical or psychiatric condition that, in the investigator's opinion, may preclude participation in this study; or * cognitive or visual impairment that would interfere with completing a self-administered questionnaire.

Keywords: glaucoma open angle glaucoma ocular hypertension compliance
fiber intake in an end stage renal disease (esrd) population followed over 2 years

Conditions: Cardiovascular Outcome; Kalemia Control; Lipid Profile

Summary: our research involves the detailed description of the content of the diet of x dialysis patients. for our purpose we used a newly developed "food frequency questionnaire". this is the first validated questionnaire specific for dialysis patients and we were the first to use it. our special focus was the fiber content in the diet of our patient. our thesis that they are way below the recommended guidelines for fiber intake was verified. our follow will evaluate the effect of such at diet, mostly cardiovascular.


Eligibility criteria:
inclusion criteria: * patients with end stage renal disease on hemodialysis * patients who are able to give informed consent exclusion criteria: * pregnant women. * cognitively impaired patients * peg feeding

Keywords: fiber dialysis renal replacement therapy food frequency questionnaire ffq dietary counseling
warm patch decrease propofol injection pain

Conditions: Pain Syndrome; Propofol Infusion Syndrome; Injection Site Irritation

Summary: propofol causes injection pain is still a common clinical unsolved problem. mixing a small amount of lidocaine with propofol or injecting lidocaine in advance can reduce the pain caused by propofol injection. using an air warmer to warm the arm can also reduce the pain caused by propofol injection. investors suspect that treatment with a warming patch (covering the injection site) can also reduce the pain caused by propofol injection.

this is a single-center randomized controlled clinical study. purpose of this study is to explore whether the coverage of the warming patch (for 5min before injection) can reduce the pain induced by propofol injection. the patients included in the study were randomly divided into two groups. the group w used a warming patch to cover the injection site, and the group c used a cotton pad to cover the injection site. after 5 minutes of coverage, the propofol injection was induced, and the patient's complaint of pain (calling or arm withdrawal) during propofol injection was observed, and the patient's recall of the pain score during induction after the patient recovered. after the patients regained consciousness, the data of the two groups were compared to determine whether the use of the warming patch could reduce the pain caused by propofol injection.

Eligibility criteria:
inclusion criteria: * no peripheral phlebitis * no history of raynaud's syndrome * no history of smoking or alcoholism * body mass index bmi\<28 kg/cm2 exclusion criteria: * refusal of anesthesia * previous injection pain caused by propofol * difficulty in exposing the veins on the back of the hand or difficulty in venipuncture * complained of pain after normal saline infusion.

Keywords: propofol,injection,pain
b-lactam databank algorithm

Conditions: Beta Lactam Adverse Reaction

Summary: background: antibiotic allergy constitutes a major health problem with serious medical and financial consequences when under- but also overdiagnosed. about one and a half million belgians report having an allergy to penicillin. however, in 1.35 million (90%) of these "penicillin allergies", the suspicion is wrong. the issue of false penicillin allergy is therefore seen as an important medical problem with significant implications for the individual patient but also for society. today, therefore, there is a global consensus to contain the pandemic of false penicillin allergy as much as possible. this should ultimately lead to correct antibiotic policies for the patient and reduce antibiotic resistance and the cost to society. the problem with this is that there is no diagnostic test that one can perform on a population of one and a half million people. this is practically and financially unfeasible. so there is a need for proper risk stratification based on anamnestic data to better guide our diagnostics. specific question: the investigators currently have a database of about 1000 patients with a possible hypersensitivity to antibiotics who have been fully diagnosed according to current guidelines. the aim of the study is to use this database to see whether a tool can be developed to reliably perform an initial "screening" to determine in whom further testing is necessary and in whom, based purely on the story, it can be decided that the likelihood of penicillin allergy is extremely low and additional diagnostics are unnecessary.


Eligibility criteria:
inclusion criteria: * adults and minors with a suspected allergy to beta-lactam antibiotics exclusion criteria: -
study on the safety, tolerability, and preliminary efficacy of 161tb-nym032 in patients with metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer, MCRPC; Cancer

Summary: 161tb-nym032 is a radiopharmaceutical labeled with a psma ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.


Eligibility criteria:
\*\*1. inclusion criteria\*\* 1. the participant voluntarily signs the informed consent form and is able to complete the trial according to the protocol requirements. 2. male, aged 18 years or older. 3. diagnosed with metastatic castration-resistant prostate cancer (mcrpc) as per pcwg3 criteria. 4. positive results on 68ga-nym032 positron emission tomography (pet)/computed tomography (ct) scan. 5. must have received at least one naad treatment (e.g., enzalutamide and/or abiraterone) or at least one taxane-based treatment regimen, or be intolerant to or refuse taxane therapy for metastatic castration-resistant prostate cancer. 6. ecog performance status of 0-2. 7. expected survival of ≥6 months. 8. laboratory parameters must meet the following: 1. alt and ast must not exceed 3 times the upper limit of normal (uln); bun and cr must not exceed 1.5 times the uln. 2. blood counts: wbc ≥3.5×10\^9/l, plt ≥100×10\^9/l, hb ≥90 g/l.
efficacy and safety of adalimumab in adult chinese subjects with active ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: study of the efficacy and safety of adalimumab compared with placebo in adult chinese participants with ankylosing spondylitis (as) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (nsaids)

adults with active ankylosing spondylitis (as) were randomized in a 2:1 ratio to receive treatment with adalimumab 40 mg every other week (eow) or matching placebo, given subcutaneously (sc), in the 12-week double-blind (db) phase. randomized participants received one sc injection of the appropriate db study medication (adalimumab 40 mg or matching placebo) at week 0 and then eow until week 10. participants who completed the db phase could enter the 12-week open-label (ol) phase, during which all participants received treatment with adalimumab 40 mg eow, starting at weeks 12 through 22. no study drug was administered or injected at the final study visit (week 24). a follow-up visit occurred 70 days after the last dose of study drug (in db or ol phases) to obtain information on any ongoing or new adverse events (aes).

Eligibility criteria:
inclusion criteria: * age 18 through 65 years * has a diagnosis of ankylosing spondylitis (as) based on the modified new york criteria * has active as, as defined by fulfillment of at least 2 of the following 3 conditions at both screening and baseline visits: * basdai score at least 4 cm * total back pain on a visual analog scale (vas) at least 40 mm * morning stiffness at least 1 hr * has inadequate response to or intolerance to one or more non-steroidal anti-inflammatory drugs (nsaids) as defined by the investigator exclusion criteria: * has total spinal ankylosis (bamboo spine) * has undergone spinal surgery or joint surgery involving joints assessed within 2 months prior to baseline * has extra-articular manifestations (i.e., psoriasis, uveitis, inflammatory bowel disease) that is not clinically stable, as defined by the investigator's best clinical judgment, for at least 28 days prior to baseline * has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to baseline * has prior exposure to any biologic therapy with potential therapeutic impact on as, including anti-tnf (tumor necrosis factor) therapy

Keywords: ankylosing spondylitis china
resume walking by an interactive mobile robot of rehabilitation after vascular stroke (cerebral vascular stroke) in combination with traditional reeducation

Conditions: Stroke Sequelae

Summary: the recovery of a balance and gait is a primary objective for geriatric, neurological or orthopedic rehabilitation. since the 80s, many walking robots were proposed. despite encouraging results, the use of robotic equipment for gait training remains limited, even if they meet a strong social demand. the reasons for this situation are economic, but also related to the non consideration of the context of utilization . this project aimed at developping a mobile and interactive robot, dedicated to the rehabilitation of balance and gait at an early stage. it was intended for patients with impaired walking vascular neurological, traumatic or associated with chronic neurological disease. the aim of the study is to study the effectiveness of the prototype (interactive walking mobile robot).


Eligibility criteria:
inclusion criteria: * male and female patients, aged at least 18 years and at most 80 years old -size at least equal to 150 cm and less than or equal to 190 cm (robot design) * having signed free informed consent in writing, * personal history of stroke with ischemic or hemorrhagic cause, right or left hemispherical, localized in addition or under tentorial * single or multiple stroke. * post stroke period: acute sub (2 weeks 6 months) * left or right hemiparesis resulting from stroke * gait or balance disorders related to the consequences of stroke * minimum berg score: 3 * hospitalization in a cpr service in complete hospitalization, week or day * medical stability, ie not presenting a cardiovascular, biological or other imbalance against the rehabilitation of walking * patient affiliated to a social security scheme exclusion criteria: * patient with a pacemaker * patient with a very open wound * weight less than 40 kg * weight greater than 105 kg (total maximum weight supported by the robot: 120 kg) - fac \> 4 and lack of technical aids for walking (e.g., single cane, tripod cane, rollator). * major persons subject to legal protection (safeguard of justice, guardianship, guardianship), persons deprived of their liberty * patients currently included in another research protocol with an influence on balance and walking * refusal of the patient to participate in the study * pregnant and lactating women, * with major cognitive or mood disorders, - being unable to give their consent.
trns combined to cognitive training in children with dyscalculia

Conditions: Developmental Dyscalculia

Summary: the present study grounds on the absence of evidence-based treatment in individuals with developmental dyscalculia (dd). at this topic, the present study will explore the potential effect of transcranial random noise stimulation (trns) over dorsolateral prefrontal cortex (dlpfc) or posterior parietal cortex (ppc), cerebral areas usually disrupted in individuals with dd, in addition to a usual treatment such as cognitive training. therefore, the investigators hypothesized that active trns over dlpfc or ppc combined to cognitive training will boost math and math-related skills in children and adolescents with dd, modulating theta/beta ratio around stimulated cerebral network. on the contrary, sham trns (placebo) over dlpfc or ppc combined to cognitive training will not have significant effect in improving math skills. further, both active and sham trns combined to cognitive training will be safe and well tolerated.

the study design is randomized stratified, double blind, placebo-controlled. a group of children and adolescents with dd will be selected and randomly assigned to three different conditions: 1. trns over bilateral dlpfc + cognitive training (brainstim dlpfc); 2. trns over bilateral ppc (brainstim ppc) + cognitive training; 3. sham trns (bilateral dlpfc/bilateral ppc; brainstim sham) + cognitive training. in this project, the investigators will work to understand whether a brain-based intervention, with the use of trns, combined to a usual treatment can improve the outcome of individual with dd. the protocol will allow the investigators to: 1. testing the critical role of two brain regions (dlpfc or ppc) usually involved in numerical abilities and disrupted in individuals with dd; 2. examining the neural changes (using eeg recordings) due to cognitive training without trns (brainstim sham) and with trns (brainstim dlpfc; brainstim ppc); 3. predicting training outcomes based on math-related skills; 4. testing the critical role of neural markers at developmental ages using a closed-loop trns to improve learning and cognitive outcomes from the training; 5. investigating the safety and tolerability of trns. the investigator's overarching goal is to provide a scientific foundation for devising new rehabilitation strategies in dd.

Eligibility criteria:
inclusion criteria: * children and adolescents with dd (total quotient of bde-2 ≤ 70) * iq ≥ 85 exclusion criteria: * having a comorbidity with an important medical conditions; * having neurological diseases; * having epilepsy o family history of epilepsy; * receiving a treatment for dd in the previous three months before the baseline screening;

Keywords: children adolescents trns transcranial random noise stimulation eeg numerical abilities neurodevelopmental disorders non-invasive brain stimulation transcranial electrical stimulation
study with m2es and gemcitabine for patients with advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: phase i trail will be conducted to evaluate the safety of m2es in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.

phase i trail will be conducted to determine the mtd and safety of m2es(administered intravenous infusion on days 1,8,15,21of a 28-day cycle) in combination with gemcitabine (1000 m/m2). gemcitabine will be administered as an intravenous infusion on days 1, 8, and 15 of each 28-day cycle,at the same time determine the safety and efficiency of this combined regime.

Eligibility criteria:
inclusion criteria: 1. patients had histologically or cytologically confirmed pancreatic adenocarcinoma that was not amenable to potentially curative surgery. 2. no prior chemotherapy was allowed. 3. prior radiation therapy was allowed provided that the only sites of measurable disease were not located within the radiation port. 4. 18 to 60 years of age 5. karnofsky performance status (kps) of 60-100 points 6. unidimensionally measurable disease as defined by response evaluation criteria in solid tumors (recist) criteria 7. adequate hematologic, renal, and hepatic function was required as dewned by the following: wbc ≥4×109/l, absolute neutrophil count ≥ 1.5×109/l, platelet count ≥100×109/l, hemoglobin ≥ 9g/dl, total bilirubin ≤2 upper limit of normal \[uln\],ast ≤ 1.5 uln, or ≤ 3 uln if there was evidence of liver metastases; alkaline phosphatase ≤ 1.5 uln, or ≤ 3 uln if there was evidence of liver metastases; creatinine clearance ≥50 ml/min. 8. life expectancy of at least 12 weeks. 9. all patients provided written informed consent according to federal and institutional guidelines. exclusion criteria: 1. patients had clinically apparent cns disease ( primary brain tumors, tumor related apoplexy, cns metastases, carcinomatous meningitis.) 2. another active malignancy, or any history of other malignancy within the past 5 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix. 3. more than 4 weeks intervals between the last administration of the targeted therapy regimen and study entry. 4. radiation therapy have not been completed 4 weeks before enrollment. 5. major surgery within the prior 4 weeks; 6. participating any clinical trial within the prior 4 weeks; 7. pregnant or lactating women. 8. tumor involvement of major blood vessels 9. uncontrolled intercurrent illness as following: prior or ongoing uncontrolled hypertension;angina pectoris; congestive cardiac failure; myocardial ischemia, infarction, uncompensated coronary artery disease within the past 6 months; uncontrolled arrhythmia; uncontrolled diabetes mellitus; uncontrolled infection. 10. chronic renal disease. 11. urine protein ≥ 500 mg in 24 hours; 12. prior history of gastrointestinal bleeding, hemoptysis, bleeding diathesis. 13. pulmonary embolus, or deep venous thrombosis 14. ecg: qtc ≥ 480 ms 15. patients on therapeutic doses of heparin or antiplatelet agents. 16. patients who received thrombolytic agents or who required full-dose anticoagulation
pharmacodynamic profile of spd489 in healthy adult males undergoing a nocturnal period of acute sleep loss

Conditions: Sleep Deprivation

Summary: this is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of spd489 in healthy adult male undergoing acute sleep deprivation.


Eligibility criteria:
inclusion criteria: * male subjects between the ages of 18-40 years. * the subject is in good health and must have a satisfactory medical assessment with no clinically significant and relevant abnormalities (of medical history, physical examination, electrocardiogram (ecg), clinical laboratory evaluation (hematology, biochemistry, and urinalysis). * subject has a history of regular sleep-wake habits, routinely spending 6.5-8 hours in bed nightly, and does not oversleep by more than 3 hours on weekends. * subject has the ability to provide written, signed, and dated (personally) informed consent to participate in the study, in accordance with the international conference on harmonisation good clinical practice guideline e6 and applicable regulations, before completing any study-related procedures. exclusion criteria: * current or relevant previous history of serious, severe, or unstable (acute or progressive) physical or psychiatric illness, any medical disorder that may require treatment or make this subject unlikely to fully complete the study, or any condition that presents undue risk from spd489 or armodafinil or procedures. comorbid psychiatric diagnosis will be established by a psychiatric evaluation that includes the mini international neuropsychiatric interview (mini)-plus. * subject is currently considered a suicide risk, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating suicidal ideation. * subject has a known or suspected sleep disorder, or another disorder associated with excessive daytime sleepiness, or any other diagnosis that would interfere with assessing sleepiness in subjects with study related induced sleepiness or abnormal findings on the initial psg conducted on day -1 such as, but not limited to, apnea-hypopnea index (ahi) or periodic limb movement arousal index (plmai) \>10.